Threshold Pharmaceuticals (THLD +4.5%), which rallied today after its TH-302 drug received orphan status from the FDA, falls 2.3% AH after providing detailed clinical results for the drug's Phase 2b trials, which evaluate its efficacy in treating pancreatic cancer.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/